Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVELIA: TOL2506 in Premenopausal HR+/HER2- Breast Cancer
NCT04906395Phase 3Active, not recruiting
- Sponsor
- Tolmar
- Start
- Jul 2021
- Primary completion
- Jan 2027
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of leuprolide acetate in breast cancer, sponsored by Tolmar. Primary endpoint: Suppression of ovarian function at 6 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
leuprolide acetate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04906395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906395.